A novel potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitor of heat shock protein 90 (Hsp90). It has been shown to induce degradation of multiple client proteins, cell-cycle block, apoptosis, and inhibits cell proliferation in triple-negative breast cancer (TNBC) lines, subsequently leading to tumor growth inhibition in mouse xenograft models.
